ADMA Biologics Inc (NASDAQ:ADMA) Given Consensus Recommendation of “Hold” by Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has been given an average recommendation of “Hold” by the five ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

Several brokerages have issued reports on ADMA. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Zacks Research cut ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. Mizuho reduced their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Canaccord Genuity Group reduced their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th.

Insider Activity

In other ADMA Biologics news, Director Jerrold B. Grossman acquired 12,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. This represents a 2.12% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Westfield Capital Management Co. LP bought a new stake in ADMA Biologics during the third quarter worth about $74,866,000. Janus Henderson Group PLC raised its holdings in ADMA Biologics by 3,906.1% during the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after acquiring an additional 3,838,158 shares in the last quarter. Capital Research Global Investors raised its holdings in ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after acquiring an additional 3,383,559 shares in the last quarter. Caligan Partners LP bought a new stake in ADMA Biologics during the third quarter worth about $38,653,000. Finally, UBS Group AG raised its holdings in ADMA Biologics by 129.9% during the fourth quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock worth $83,345,000 after acquiring an additional 2,581,670 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 0.1%

Shares of ADMA Biologics stock opened at $7.97 on Tuesday. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $22.37. The business has a 50-day moving average of $9.25 and a two-hundred day moving average of $14.43. The company has a market capitalization of $1.85 billion, a P/E ratio of 11.72 and a beta of 0.72. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. During the same period in the prior year, the company earned $0.11 earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities analysts predict that ADMA Biologics will post 0.84 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.